Revenue YoY
+5.92%
Operating Income YoY
-5.27%
Net Income YoY
-1.70%
Net Margin Δ
-234 bps
Net income bridge for Regeneron Pharmaceuticals (REGN) — TTM through Q1 2026 vs TTM through Q1 2025
Δ Net income: -$75.9M-1.70%
Profit bridge breakdown for Regeneron Pharmaceuticals (REGN) — TTM through Q1 2026 vs TTM through Q1 2025
| Driver | Contribution | % of Δ |
|---|---|---|
| Prior Net Income | $4.5B | — |
| Revenue | $834M | +1,098.7% |
| Cost of Revenue | -$305M | -401.6% |
| Operating Expenses | -$731M | -963.1% |
| Other Income / Expense | $375M | +493.5% |
| Income Tax | -$249M | -327.5% |
| Net Income | $4.42B | — |
- Prior Net Income$4.5B
- Revenue$834M
- Cost of Revenue-$305M
- Operating Expenses-$731M
- Other Income / Expense$375M
- Income Tax-$249M
- Net Income$4.42B
Identity check: drivers reconcile to ΔNI within $0.00 ✓
Want the full P&L structure?Income Statement Waterfall
Frequently asked questions
Data & methodology
Regeneron Pharmaceuticals (REGN) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Cash Flow
Forecast & Valuation
Operations
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement
Capital Return
How this company returns cash to shareholders — buybacks, dividends, and stock splits.